T. Clackson

发表

A hot spot of binding energy in a hormone-receptor interface

T. Clackson, J. Wells, J. Wells, 1995, Science.

Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity.

T. Clackson, J. Wells, M. Ultsch, 1998, Journal of molecular biology.

Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial

T. Clackson, A. Tolcher, J. Kreisberg, 2012, Cancer Chemotherapy and Pharmacology.

Making antibody fragments using phage display libraries

T. Clackson, G. Winter, A. Griffiths, 1991, Nature.

Ponatinib in refractory Philadelphia chromosome-positive leukemias.

I. Flinn, T. Clackson, H. Kantarjian, 2012, The New England journal of medicine.

Evaluation of a rapamycin-regulated serotype 2 adeno-associated viral vector in macaque parotid glands.

T. Clackson, V. Rivera, C. Dunbar, 2010, Oral diseases.

Rapamycin control of transgene expression from a single AAV vector in mouse salivary glands

T. Clackson, V. Rivera, B. Baum, 2006, Gene Therapy.

Structural Analysis of DFG‐in and DFG‐out Dual Src‐Abl Inhibitors Sharing a Common Vinyl Purine Template

T. Clackson, T. Zhou, T. Sawyer, 2009, Chemical biology & drug design.

generate primary gene-modified T cells for adoptive immunotherapy CD28 costimulation and immunoaffinity-based selection efficiently

S. Heimfeld, T. Clackson, S. Riddell, 2012 .

CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy.

S. Heimfeld, T. Clackson, S. Riddell, 2003, Blood.

Pharmacologically regulated in vivo selection in a large animal.

C. von Kalle, A. Gown, T. Clackson, 2002, Blood.

Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers

T. Clackson, S. Oliver, D. Dalgarno, 2001, Journal of clinical pharmacology.

Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye.

T. Clackson, J. Bennett, James M. Wilson, 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

Regulated expression of erythropoietin from an AAV vector safely improves the anemia of beta-thalassemia in a mouse model.

T. Clackson, James M. Wilson, V. Rivera, 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model.

S. Heimfeld, T. Clackson, S. Riddell, 2004, Blood.

Pharmacologically regulated regeneration of functional human pancreatic islets.

T. Clackson, G. Kobinger, J. Markmann, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer.

L. Rozamus, T. Clackson, James M. Wilson, 2005, Blood.

Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation

T. Clackson, M. Baccarani, J. Dipersio, 2011 .

A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease.

T. Clackson, M. Gilman, C. Bordignon, 2001, Blood.

Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC

T. Clackson, R. Anjum, V. Rivera, 2012 .

First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.

T. Clackson, A. Shaw, S. Gettinger, 2013 .

Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia

T. Clackson, B. Druker, M. Deininger, 2010, Clinical Cancer Research.

Megavesicles Implicated in the Rapid Transport of Intracisternal Aggregates across the Golgi Stack

J. Rothman, L. Orci, T. Clackson, 2000, Cell.

Investigating protein-ligand interactions with a mutant FKBP possessing a designed specificity pocket.

L. Rozamus, D. Holt, T. Clackson, 2000, Journal of medicinal chemistry.

A stability switch for proteins.

T. Clackson, 2006, Chemistry & biology.

Regulation of gene expression by synthetic dimerizers with novel specificity.

L. Rozamus, D. Holt, T. Clackson, 2003, Bioorganic & medicinal chemistry letters.

Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials

I. Flinn, T. Clackson, M. Baccarani, 2014 .

P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial: Topic: ALK Clinical

Edward S. Kim, H. Groen, T. Clackson, 2017 .

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.

T. Clackson, M. Baccarani, R. Clark, 2016, The Lancet. Oncology.

JAK2, complemented by a second signal from c‐kit or flt‐3, triggers extensive self‐renewal of primary multipotential hemopoietic cells

T. Clackson, J. Ihle, C. A. Blau, 2002, The EMBO journal.

Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2014 .

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

I. Flinn, T. Clackson, H. Kantarjian, 2010 .

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

T. Clackson, R. Anjum, V. Rivera, 2016, Clinical Cancer Research.

Rapamycin-regulated control of antiangiogenic tumor therapy following rAAV-mediated gene transfer.

T. Clackson, V. Rivera, K. Jooss, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2012 .

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Martin C. Müller, J. Hodgson, T. Clackson, 2016, Blood.

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study

I. Flinn, T. Clackson, H. Kantarjian, 2013, British journal of haematology.

Abstract 853: Ponatinib, a potent pan-BCR-ABL inhibitor, retains activity against gatekeeper mutants of FLT3, RET, KIT, PDGFRα/β and FGFR1

T. Clackson, V. Rivera, M. Wong, 2012 .

Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.

I. Flinn, T. Clackson, H. Kantarjian, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 1 Trial of Oral AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Other Hematologic Malignancies: First Results of Safety and Clinical Activity against T315I and Resistant Mutations.

I. Flinn, T. Clackson, H. Kantarjian, 2009 .

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2012 .

Potent Antitumor Activity of AP24534, An Orally Active Inhibitor of Bcr-Abl, Flt3 and Other Kinases, in Both in Vitro and in Vivo Models of Acute Myeloid Leukemia (AML)

T. Clackson, L. Berk, V. Rivera, 2008 .

Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).

T. Clackson, B. Druker, A. Corbin, 2007 .

Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066)

T. Clackson, R. Anjum, V. Rivera, 2010 .

Abstract #3738: Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK)

T. Clackson, R. Anjum, V. Rivera, 2009 .

411 Pharmacodynamic evaluation of the mTOR inhibitor AP23573 in phase 1 clinical trials

M. Ratain, T. Clackson, A. Tolcher, 2004 .

Anti-proliferative activity of the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents

T. Clackson, V. Rivera, T. Keenan, 2004 .

Assessment of the safety and biodistribution of a regulated AAV2 gene transfer vector after delivery to murine submandibular glands.

T. Clackson, J. Chiorini, V. Rivera, 2011, Toxicological sciences : an official journal of the Society of Toxicology.

Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial

P. Wen, T. Clackson, M. Vogelbaum, 2012, Cancer Chemotherapy and Pharmacology.

Abstract 5655: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions.

T. Clackson, R. Anjum, V. Rivera, 2013 .

Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients

J. Fletcher, T. Clackson, M. Heinrich, 2014, Clinical Cancer Research.

A First-In-Human Dose-Finding Study of the Alk/Egfr Inhibitor AP26113 in Patients with Advanced Malignancies

T. Clackson, A. Shaw, S. Gettinger, 2012 .

A humanized system for pharmacologic control of gene expression

Shannon R. Magari, Victor M. Rivera, D. Holt, 1996, Nature Medicine.

Dissecting the Functions of Proteins and Pathways using Chemically Induced Dimerization

T. Clackson, 2006, Chemical biology & drug design.

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

T. Clackson, B. Druker, A. Corbin, 2009, Cancer cell.

Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2013 .

1048. Long-Term Regulated Gene Expression in Non-Human Primates Using a Single Non-Recombinogenic AAV Vector

T. Clackson, James M. Wilson, L. Berk, 2004 .

Differences in F36VMpl-based in vivo selection among large animal models.

S. Heimfeld, T. Clackson, H. V. von Recum, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum.

L Orci, J. Rothman, L. Orci, 2000, Science.

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.

Wei-Sheng Huang, Jan Romero, Shuangying Liu, 2010, Journal of medicinal chemistry.

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.

T. Clackson, R. Anjum, V. Rivera, 2016, Journal of medicinal chemistry.

In vitro selection from protein and peptide libraries.

T. Clackson, J. Wells, J. Wells, 1994, Trends in biotechnology.

Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity.

Shannon R. Magari, L. Rozamus, D. Holt, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Direct clone characterization from plaques and colonies by the polymerase chain reaction.

T. Clackson, D. Güssow, Detlef Gussow, 1989, Nucleic acids research.

Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

T. Clackson, B. Druker, J. Tyner, 2011, Molecular Cancer Therapeutics.

Preclinical Development Potent Activity of Ponatinib ( AP 24534 ) in Models of FLT 3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

T. Clackson, B. Druker, J. Tyner, 2011 .

By–Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling

Andrew D. Griffiths, James D. Marks, Jacqueline M. Bye, 1992, Bio/Technology.

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer.

Kwok-Kin Wong, T. Clackson, A. Gould, 2021, Cancer discovery.

A versatile synthetic dimerizer for the regulation of protein-protein interactions.

D. Holt, T. Clackson, V. Rivera, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen

T. Clackson, R. Anjum, V. Rivera, 2011, Chemical biology & drug design.

Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

T. Clackson, V. Rivera, T. Zhou, 2011, Chemical biology & drug design.

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

T. Clackson, R. Bohacek, B. Druker, 2004, Blood.

'Sticky feet'-directed mutagenesis and its application to swapping antibody domains.

T. Clackson, G. Winter, 1989, Nucleic acids research.

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

J. Blay, G. Demetri, T. Clackson, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models

T. Clackson, V. Rivera, D. Clapham, 2011, Molecular Cancer Therapeutics.

Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

T. Clackson, L. Berk, V. Rivera, 2011, Molecular Cancer Therapeutics.

Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

T. Clackson, V. Rivera, W. Shakespeare, 2012, Molecular Cancer Therapeutics.

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models

T. Clackson, V. Rivera, Frank Y Wang, 2012, International journal of oncology.

Preclinical Development Ridaforolimus ( AP 23573 ; MK-8669 ) , a Potent mTOR Inhibitor , Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

T. Clackson, L. Berk, V. Rivera, 2011 .

Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors.

T. Clackson, V. Rivera, T. Zhou, 2013, Journal of medicinal chemistry.

Discovery of Mobocertinib, a Potent, Oral Inhibitor of EGFR Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer.

T. Clackson, A. Gould, V. Rivera, 2022, Bioorganic & medicinal chemistry letters.

Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC).

T. Clackson, A. Shaw, S. Gettinger, 2014 .

Controlling mammalian gene expression with small molecules.

T. Clackson, 1997, Current opinion in chemical biology.

Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy.

T. Clackson, R. Vile, K. Harrington, 2003, Cancer research.

A system for small-molecule control of conditionally replication-competent adenoviral vectors.

T. Clackson, R. Vile, H. Chong, 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

Constitutive and regulated expression of processed insulin following in vivo hepatic gene transfer

T. Clackson, G. Gao, S. Raper, 2002, Gene Therapy.

AP24163 Inhibits the Gatekeeper Mutant of BCR‐ABL and Suppresses In vitro Resistance

John T. Powers, G. Daley, T. Clackson, 2010, Chemical biology & drug design.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

T. Clackson, M. Baccarani, J. Dipersio, 2013, The New England journal of medicine.

9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.

G. Daley, T. Clackson, M. Azam, 2009, Journal of medicinal chemistry.

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.

T. Clackson, B. Druker, A. Corbin, 2006 .

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models

T. Clackson, V. Rivera, M. Wongchenko, 2013, Cancer Chemotherapy and Pharmacology.

Preclinical Development Ponatinib ( AP 24534 ) , aMultitargeted Pan-FGFR Inhibitorwith Activity in Multiple FGFR-Ampli fi ed or Mutated Cancer Models

T. Clackson, V. Rivera, W. Shakespeare, 2012 .

Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.

Wei-Sheng Huang, Jan Romero, Shuangying Liu, 2011, Bioorganic & medicinal chemistry letters.

Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.

T. Clackson, T. Sawyer, W. Shakespeare, 2008, Bioorganic & medicinal chemistry letters.

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

T. Clackson, A. Shaw, S. Gettinger, 2016, The Lancet. Oncology.

Phage display : a practical approach

T. Clackson, H. Lowman, Tim Clackson, 2004 .

Dimerizer-regulated gene expression.

T. Clackson, R. Pollock, 2002, Current opinion in biotechnology.

Regulation of endogenous gene expression with a small-molecule dimerizer

T. Clackson, K. Linher, R. Pollock, 2002, Nature Biotechnology.

Regulated gene expression systems

T. Clackson, T Clackson, 2000, Gene Therapy.

Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats.

T. Clackson, L. Berk, V. Rivera, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Translational Research in Academia and Industry

T. Clackson, Tim Clackson, 2006, Experimental biology and medicine.

Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group.

T. Clackson, A. Rundle, L. Carlsson, 1995, The New England journal of medicine.

A ligand-reversible dimerization system for controlling protein-protein interactions.

D N Woolfson, D. Holt, M. Hatada, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Redesigning small molecule-protein interfaces.

T. Clackson, 1998, Current opinion in structural biology.

Breaking and entering

T. Clackson, Tim Clackson, 2006, Nature chemical biology.

Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC).

T. Clackson, A. Shaw, S. Gettinger, 2015 .

Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)

T. Clackson, M. Baccarani, R. Clark, 2014 .

Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

I. Flinn, T. Clackson, H. Kantarjian, 2014 .

ATP Dependent Efflux Transporters ABCB1 and ABCG2 Are Unlikely to Impact the Efficacy, or Mediate Resistance to the Tyrosine Kinase Inhibitor, Ponatinib

T. Clackson, D. White, T. Hughes, 2011 .

EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.

T. Clackson, M. Baccarani, H. Kantarjian, 2014 .

Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies

I. Flinn, T. Clackson, H. Kantarjian, 2011 .

INTRATUMORAL DNA-BASED GENE TRANSFER AS AN EFFICIENT DELIVERY APPROACH TO COMBINE CHECKPOINT-INHIBITING ANTIBODIES WITH INTERLEUKIN 12

T. Clackson, John S. Williams, O. Ronan, 2020 .

1292PALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA.

T. Clackson, A. Shaw, S. Gettinger, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis

Xin Zhang, T. Clackson, A. Shaw, 2018, Frontiers in Oncology.

Abstract 3623: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK)

Juan J. Miret, Wei-Sheng Huang, Shuangying Liu, 2010 .

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

T. Clackson, H. Kantarjian, J. Cortes, 2017 .

321 POSTER A phase I trial evaluating pharmacodynamics of deforolimus (AP23573, MK-8669) delivered orally on multiple dosing schedules

T. Clackson, C. Britten, L. Berk, 2008 .

Delivery of a stringent dimerizer-regulated gene expression system in a single retroviral vector.

T. Clackson, R. Issner, V. Rivera, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Martin C. Müller, T. Clackson, M. Baccarani, 2013 .

Abstract 3560: Ponatinib (AP24534), a potent pan-FGFR inhibitor with activity in multiple FGFR-driven cancer models

T. Clackson, V. Rivera, W. Shakespeare, 2011 .

Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).

I. Flinn, T. Clackson, H. Kantarjian, 2015 .

Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates.

T. Clackson, J. Bennett, James M. Wilson, 2005, Human gene therapy.

Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Martin C. Müller, T. Clackson, M. Baccarani, 2013 .

Synthesis and activity of bivalent FKBP12 ligands for the regulated dimerization of proteins.

D. Holt, T. Clackson, V. Rivera, 1998, Bioorganic & medicinal chemistry.

Structure-based design of AP23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy.

L. Rozamus, T. Clackson, R. Bohacek, 2004 .

Comprehensive Analysis Of The In Vitro Potency Of Ponatinib, and All Other Approved BCR-ABL Tyrosine Kinase Inhibitors (TKIs), Against a Panel Of Single and Compound BCR-ABL Mutants

T. Clackson, Tzu-Hsiu Chen, V. Rivera, 2013 .

Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

T. Clackson, V. Rivera, T. Zhou, 2011, Chemical biology & drug design.

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Martin C. Müller, T. Clackson, M. Baccarani, 2012 .

Abstract 2726: RET fusions identified in colorectal cancer PDX models are sensitive to the potent RET inhibitor ponatinib

T. Clackson, Tzu-Hsiu Chen, V. Rivera, 2014 .

A ligand-reversible dimerization system for controlling protein-protein interactions.

M. Hatada, T. Clackson, D. Woolfson, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Abstract 2827: Discovery of AP26113, a potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants

T. Clackson, V. Rivera, W. Shakespeare, 2015 .